|
1
|
Galambos AR, Essmat N, Lakatos PP, Szücs E, Boldizsár I, Abbood SK, Karádi DÁ, Kirchlechner-Farkas JM, Király K, Benyhe S, Riba P, Tábi T, Harsing LG, Zádor F, Al-Khrasani M. Glycine Transporter 1 Inhibitors Minimize the Analgesic Tolerance to Morphine. Int J Mol Sci 2024; 25:11136. [PMID: 39456918 PMCID: PMC11508341 DOI: 10.3390/ijms252011136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2024] [Revised: 10/11/2024] [Accepted: 10/15/2024] [Indexed: 10/28/2024] Open
Abstract
Opioid analgesic tolerance (OAT), among other central side effects, limits opioids' indispensable clinical use for managing chronic pain. Therefore, there is an existing unmet medical need to prevent OAT. Extrasynaptic N-methyl D-aspartate receptors (NMDARs) containing GluN2B subunit blockers delay OAT, indicating the involvement of glutamate in OAT. Glycine acts as a co-agonist on NMDARs, and glycine transporters (GlyTs), particularly GlyT-1 inhibitors, could affect the NMDAR pathways related to OAT. Chronic subcutaneous treatments with morphine and NFPS, a GlyT-1 inhibitor, reduced morphine antinociceptive tolerance (MAT) in the rat tail-flick assay, a thermal pain model. In spinal tissues of rats treated with a morphine-NFPS combination, NFPS alone, or vehicle-comparable changes in µ-opioid receptor activation, protein and mRNA expressions were seen. Yet, no changes were observed in GluN2B mRNA levels. An increase was observed in glycine and glutamate contents of cerebrospinal fluids from animals treated with a morphine-NFPS combination and morphine, respectively. Finally, GlyT-1 inhibitors are likely to delay MAT by mechanisms relying on NMDARs functioning rather than an increase in opioid efficacy. This study, to the best of our knowledge, shows for the first time the impact of GlyT-1 inhibitors on MAT. Nevertheless, future studies are required to decipher the exact mechanisms.
Collapse
Affiliation(s)
- Anna Rita Galambos
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, H-1085 Budapest, Hungary; (A.R.G.); (N.E.); (I.B.J.); (S.K.A.); (D.Á.K.); (J.M.K.-F.); (K.K.); (P.R.); (L.G.H.J.)
- Center for Pharmacology and Drug Research & Development, Semmelweis University, Üllői út 26., H-1085 Budapest, Hungary; (P.P.L.); (T.T.)
| | - Nariman Essmat
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, H-1085 Budapest, Hungary; (A.R.G.); (N.E.); (I.B.J.); (S.K.A.); (D.Á.K.); (J.M.K.-F.); (K.K.); (P.R.); (L.G.H.J.)
- Center for Pharmacology and Drug Research & Development, Semmelweis University, Üllői út 26., H-1085 Budapest, Hungary; (P.P.L.); (T.T.)
| | - Péter P. Lakatos
- Center for Pharmacology and Drug Research & Development, Semmelweis University, Üllői út 26., H-1085 Budapest, Hungary; (P.P.L.); (T.T.)
- Department of Pharmacodynamics, Semmelweis University, Nagyvárad tér 4, H-1089 Budapest, Hungary
| | - Edina Szücs
- Institute of Genetics, HUN-REN Biological Research Centre, Temesvári krt. 62, H-6726 Szeged, Hungary;
| | - Imre Boldizsár
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, H-1085 Budapest, Hungary; (A.R.G.); (N.E.); (I.B.J.); (S.K.A.); (D.Á.K.); (J.M.K.-F.); (K.K.); (P.R.); (L.G.H.J.)
- Center for Pharmacology and Drug Research & Development, Semmelweis University, Üllői út 26., H-1085 Budapest, Hungary; (P.P.L.); (T.T.)
| | - Sarah Kadhim Abbood
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, H-1085 Budapest, Hungary; (A.R.G.); (N.E.); (I.B.J.); (S.K.A.); (D.Á.K.); (J.M.K.-F.); (K.K.); (P.R.); (L.G.H.J.)
- Center for Pharmacology and Drug Research & Development, Semmelweis University, Üllői út 26., H-1085 Budapest, Hungary; (P.P.L.); (T.T.)
| | - Dávid Á. Karádi
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, H-1085 Budapest, Hungary; (A.R.G.); (N.E.); (I.B.J.); (S.K.A.); (D.Á.K.); (J.M.K.-F.); (K.K.); (P.R.); (L.G.H.J.)
- Center for Pharmacology and Drug Research & Development, Semmelweis University, Üllői út 26., H-1085 Budapest, Hungary; (P.P.L.); (T.T.)
| | - Judit Mária Kirchlechner-Farkas
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, H-1085 Budapest, Hungary; (A.R.G.); (N.E.); (I.B.J.); (S.K.A.); (D.Á.K.); (J.M.K.-F.); (K.K.); (P.R.); (L.G.H.J.)
- Center for Pharmacology and Drug Research & Development, Semmelweis University, Üllői út 26., H-1085 Budapest, Hungary; (P.P.L.); (T.T.)
| | - Kornél Király
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, H-1085 Budapest, Hungary; (A.R.G.); (N.E.); (I.B.J.); (S.K.A.); (D.Á.K.); (J.M.K.-F.); (K.K.); (P.R.); (L.G.H.J.)
- Center for Pharmacology and Drug Research & Development, Semmelweis University, Üllői út 26., H-1085 Budapest, Hungary; (P.P.L.); (T.T.)
| | - Sándor Benyhe
- HUN-REN Biological Research Centre, Institute of Biochemistry, Temesvári krt. 62, H-6726 Szeged, Hungary;
| | - Pál Riba
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, H-1085 Budapest, Hungary; (A.R.G.); (N.E.); (I.B.J.); (S.K.A.); (D.Á.K.); (J.M.K.-F.); (K.K.); (P.R.); (L.G.H.J.)
- Center for Pharmacology and Drug Research & Development, Semmelweis University, Üllői út 26., H-1085 Budapest, Hungary; (P.P.L.); (T.T.)
| | - Tamás Tábi
- Center for Pharmacology and Drug Research & Development, Semmelweis University, Üllői út 26., H-1085 Budapest, Hungary; (P.P.L.); (T.T.)
- Department of Pharmacodynamics, Semmelweis University, Nagyvárad tér 4, H-1089 Budapest, Hungary
| | - Laszlo G. Harsing
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, H-1085 Budapest, Hungary; (A.R.G.); (N.E.); (I.B.J.); (S.K.A.); (D.Á.K.); (J.M.K.-F.); (K.K.); (P.R.); (L.G.H.J.)
- Center for Pharmacology and Drug Research & Development, Semmelweis University, Üllői út 26., H-1085 Budapest, Hungary; (P.P.L.); (T.T.)
| | - Ferenc Zádor
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, H-1085 Budapest, Hungary; (A.R.G.); (N.E.); (I.B.J.); (S.K.A.); (D.Á.K.); (J.M.K.-F.); (K.K.); (P.R.); (L.G.H.J.)
| | - Mahmoud Al-Khrasani
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, H-1085 Budapest, Hungary; (A.R.G.); (N.E.); (I.B.J.); (S.K.A.); (D.Á.K.); (J.M.K.-F.); (K.K.); (P.R.); (L.G.H.J.)
- Center for Pharmacology and Drug Research & Development, Semmelweis University, Üllői út 26., H-1085 Budapest, Hungary; (P.P.L.); (T.T.)
| |
Collapse
|
|
2
|
Bodnar RJ. Endogenous opiates and behavior: 2023. Peptides 2024; 179:171268. [PMID: 38943841 DOI: 10.1016/j.peptides.2024.171268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/29/2024] [Revised: 06/18/2024] [Accepted: 06/19/2024] [Indexed: 07/01/2024]
Abstract
This paper is the forty-sixth consecutive installment of the annual anthological review of research concerning the endogenous opioid system, summarizing articles published during 2023 that studied the behavioral effects of molecular, pharmacological and genetic manipulation of opioid peptides and receptors as well as effects of opioid/opiate agonists and antagonists. The review is subdivided into the following specific topics: molecular-biochemical effects and neurochemical localization studies of endogenous opioids and their receptors (1), the roles of these opioid peptides and receptors in pain and analgesia in animals (2) and humans (3), opioid-sensitive and opioid-insensitive effects of nonopioid analgesics (4), opioid peptide and receptor involvement in tolerance and dependence (5), stress and social status (6), learning and memory (7), eating and drinking (8), drug and alcohol abuse (9), sexual activity and hormones, pregnancy, development and endocrinology (10), mental illness and mood (11), seizures and neurologic disorders (12), electrical-related activity and neurophysiology (13), general activity and locomotion (14), gastrointestinal, renal and hepatic functions (15), cardiovascular responses (16), respiration and thermoregulation (17), and immunological responses (18).
Collapse
Affiliation(s)
- Richard J Bodnar
- Department of Psychology and Psychology Doctoral Sub-Program, Queens College and the Graduate Center, City University of New York, USA.
| |
Collapse
|
|
3
|
Cai T, Shang K, Wang X, Qi X, Liu R, Wang X. Integration of Glutamate Dehydrogenase and Nanoporous Gold for Electrochemical Detection of Glutamate. BIOSENSORS 2023; 13:1023. [PMID: 38131783 PMCID: PMC10741451 DOI: 10.3390/bios13121023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Revised: 11/23/2023] [Accepted: 12/05/2023] [Indexed: 12/23/2023]
Abstract
Glutamate, a non-essential amino acid produced by fermentation, plays a significant role in disease diagnosis and food safety. It is important to enable the real-time monitoring of glutamate concentration for human health and nutrition. Due to the challenges in directly performing electrochemical oxidation-reduction reactions of glutamate, this study leverages the synergistic effect of glutamate dehydrogenase (GLDH) and nanoporous gold (NPG) to achieve the indirect and accurate detection of glutamate within the range of 50 to 700 μM by measuring the generated quantity of NADH during the enzymatic reaction. The proposed biosensor demonstrates remarkable performance characteristics, including a detection sensitivity of 1.95 μA mM-1 and a limit of detection (LOD) of 6.82 μM. The anti-interference tests indicate an average recognition error ranging from -3.85% to +2.60%, spiked sample recovery rates between 95% and 105%, and a relative standard deviation (RSD) of less than 4.97% for three replicate experiments. Therefore, the GLDH-NPG/GCE biosensor presented in this work exhibits excellent accuracy and repeatability, providing a novel alternative for rapid glutamate detection. This research contributes significantly to enhancing the precise monitoring of glutamate concentration, thereby offering more effective guidance and control for human health and nutrition.
Collapse
Affiliation(s)
| | | | | | | | | | - Xia Wang
- State Key Laboratory of Microbial Technology, Shandong University, Qingdao 266237, China; (T.C.); (K.S.); (X.W.); (X.Q.); (R.L.)
| |
Collapse
|